Highlights Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Market Closed - London S.E. Other stock markets 11:35:02 2024-06-03 am EDT			5-day change	1st Jan Change
14.25 ^GBX	+4.01%		+8.37%	+57.46%

May. 01	Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	MT
May. 01	Poolbeg Pharma celebrates full patent approval for Immunomodulator II	AN

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	May. 01	MT
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	May. 01	AN
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	May. 01	CI
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	Apr. 30	MT
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	Apr. 30	AN
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79	Apr. 30	MT
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	Mar. 20	AN
Poolbeg Pharma plc Announces POLB 001 US Patent Update	Mar. 20	CI
Diversified Energy offers dividend alternative	Feb. 15	AN
Katoro Gold launches fundraising, eyes board shake-up	Feb. 12	AN
Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome	Feb. 12	CI
Poolbeg Pharma hails POLB 001'S potential to treat CRS	Jan. 17	AN
Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome	Jan. 17	CI
K3 Business says cash balances ahead of forecast	Dec. 20	AN
Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully	Dec. 20	CI
Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001	Dec. 11	CI
Poolbeg hails approval; EDX links with Thermo Fisher	Nov. 21	AN
Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme	23-10-26	CI
Poolbeg Pharma Enters Partnership to Develop Metabolic Condition Treatment	23-10-17	MT
Poolbeg Pharma shares up on metabolic drug collaboration agreement	23-10-17	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Highlights

Filters